|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Human anti-NKp46 antibody for studies of NKp46-dependent NK cell function and its applications for type 1 diabetes and cancer research.
|
30536875 |
2019 |
|
Hepatitis C
|
0.030 |
Biomarker
|
disease |
BEFREE |
Similarly, ligation of NKp46 on isolated NK cells resulted in a significant reduction in the HCV copy number detected in Huh-7.5/JFH-1 coculture (multiplicity of infection: 0.01) at an effector:target ratio of 5:1 (P < 0.005).
|
22505144 |
2012 |
|
Hepatitis C
|
0.030 |
Biomarker
|
disease |
BEFREE |
However, reports on NKp46 in hepatitis C are controversial.
|
22532190 |
2012 |
|
Leukemia, Myelocytic, Acute
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our longitudinal study of AML patients showed that the NCR(dull) phenotype was acquired during leukemia development because we observed its complete (for NKp46) or partial (for NKp30) reversibility in patients achieving complete remission (CR).
|
16940427 |
2007 |
|
Virus Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
There was enhanced spread of certain tumors in 129/Sv but not C57BL/6 Ncr1(gfp/gfp) mice, and influenza virus infection was lethal in both 129/Sv and C57BL/6 Ncr1(gfp/gfp) mice.
|
16565719 |
2006 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.020 |
Biomarker
|
disease |
BEFREE |
Most importantly, we showed that a toxin-conjugated 02 inhibits the growth of NKp46-positive cells; thus, exemplifying the potential of 02 in becoming an immunotherapeutic drug to treat NKp46-dependent diseases, such as, type I diabetes and NK and T cell related malignancies.
|
30536875 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our findings demonstrate that NKp46 is essential for the development of type 1 diabetes and highlight potential new therapeutic modalities for this disease.
|
20023661 |
2010 |
|
leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our longitudinal study of AML patients showed that the NCR(dull) phenotype was acquired during leukemia development because we observed its complete (for NKp46) or partial (for NKp30) reversibility in patients achieving complete remission (CR).
|
16940427 |
2007 |
|
leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus, IL-15 signaling and NKp46 may be useful targets in the treatment of patients with T-LGL or NKT leukemia.
|
21364281 |
2011 |
|
Tuberculosis
|
0.020 |
Biomarker
|
disease |
LHGDN |
These results indicate that vimentin is involved in binding of NKp46 to M. tuberculosis H37Ra-infected mononuclear phagocytes.
|
17056548 |
2006 |
|
Complete atrioventricular block
|
0.020 |
Biomarker
|
disease |
BEFREE |
It was found that NKp46(+) NK cells were enriched in the livers of AHB and CHB patients.
|
23133672 |
2012 |
|
Childhood Leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our longitudinal study of AML patients showed that the NCR(dull) phenotype was acquired during leukemia development because we observed its complete (for NKp46) or partial (for NKp30) reversibility in patients achieving complete remission (CR).
|
16940427 |
2007 |
|
Childhood Leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus, IL-15 signaling and NKp46 may be useful targets in the treatment of patients with T-LGL or NKT leukemia.
|
21364281 |
2011 |
|
Severe Aplastic Anemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Activating receptors NKp46 and NKp44 on CD56<sup>bright</sup> NK cells were upregulated while inhibiting receptor NKG2A was downregulated in SAA.
|
30779419 |
2019 |
|
Addison Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Phenotypically, the percentage of NK cells expressing the activating receptors NKG2D and NKp46 was significantly lower in PAI, as was the surface density of NKG2D (all <i>P</i> < 0.0001).
|
28223394 |
2017 |
|
Melanoma, B16
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ncr1 overexpression in NK cells increased NK cell immunity in two hallmark Ncr1 related pathologies, influenza virus infection and B16 melanoma.
|
29026144 |
2017 |
|
Bacterial Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
NKp46/NCR1 is an activating NK-cell receptor implicated in the control of various viral and bacterial infections.
|
28643847 |
2017 |
|
Celiac Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
In paraffin biopsies, detection of >25 NKp46+ IEL per 100 epithelial cells discriminated RCDII from CD and RCDI.
|
30448772 |
2019 |
|
Colorectal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Immunocompetent NCR1-GFP mice, in which NK cells express GFP, demonstrated GFP+ NK cell infiltration of syngeneic MC38 colorectal tumors.
|
29533922 |
2018 |
|
Cystic Fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Importantly, sputa of cystic fibrosis (CF) patients, which have high concentrations of CG, also alter NKp46 on NK cells.
|
27587403 |
2017 |
|
Cytomegalovirus Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
As a result, NKGD2-deficient (Klrk1<sup>-/-</sup>) mice controlled tumors and cytomegalovirus infection better than wild-type controls through the NCR1-induced production of the cytokine IFN-γ.
|
30224819 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results demonstrate for the first time defects in NK cell-activating receptors NKG2D and NKp46 in T2D patients, and implicate the UPR pathway as a potential mechanism.
|
23638076 |
2013 |
|
Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We found that HSV titers and oHSV efficacy are increased in Ncr1(-/-) mice and a Ncr1(-/-) NK cell adoptive transfer model of glioma, respectively.
|
23178246 |
2012 |
|
Hepatitis B
|
0.010 |
Biomarker
|
disease |
BEFREE |
Frequency and role of NKp46 and NKG2A in hepatitis B virus infection.
|
28328926 |
2017 |
|
Acute monocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML.
|
29209559 |
2017 |